Drugs & Targets Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC September 27, 2024Vol.50 No.36
Regulatory News Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover designThe agency accepts the invitation September 20, 2024Vol.50 No.35By Paul Goldberg
Guest Editorial Group chairs propose funding strategy to jump-start correlative studies September 20, 2024Vol.50 No.35By Peter J. O'Dwyer
AACR progress report highlights AI’s role in research and clinical careObstacles to progress include systemic disparities and dwindling appropriations September 20, 2024Vol.50 No.35By McKenzie Prillaman
2024 Lasker Awards honor discoveries in antitumor immunity, GLP-1-based drugs, and research, advocacy in HIV/AIDS September 20, 2024Vol.50 No.35By Claire Marie Porter
In Brief Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration September 20, 2024Vol.50 No.35
In Brief Robert Jenq named director of microbiome program at City of Hope September 20, 2024Vol.50 No.35
In Brief Chapman-Davis, Romero Arenas, and Guzman named to Meyer Cancer Center inaugural DEI leadership team September 20, 2024Vol.50 No.35
In Brief Kathryn Schmitz receives 2024 Lifetime Impact Award from the President’s Council on Sports, Fitness & Nutrition September 20, 2024Vol.50 No.35
In Brief Arielle Weiss to join Fox Chase Division of Gynecologic Oncology September 20, 2024Vol.50 No.35
